Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;122(26):e2426554122.
doi: 10.1073/pnas.2426554122. Epub 2025 Jun 27.

De novo design of D-peptide ligands: Application to influenza virus hemagglutinin

Affiliations

De novo design of D-peptide ligands: Application to influenza virus hemagglutinin

Jarek Juraszek et al. Proc Natl Acad Sci U S A. 2025 Jul.

Abstract

D-peptides hold great promise as therapeutics by alleviating the challenges of metabolic stability and immunogenicity in L-peptides. However, current D-peptide discovery methods are severely limited by specific size, structure, and the chemical synthesizability of their protein targets. Here, we describe a computational method for de novo design of D-peptides that bind to an epitope of interest on the target protein using Rosetta's hotspot-centric approach. The approach comprises identifying hotspot sidechains in a functional protein-protein interaction and grafting these side chains onto much smaller structured peptide scaffolds of opposite chirality. The approach enables more facile design of D-peptides and its applicability is demonstrated by design of D-peptidic binders of influenza A virus hemagglutinin, resulting in identification of multiple D-peptide lead series. The X-ray structure of one of the leads at 2.38 Å resolution verifies the validity of the approach. This method should be generally applicable to targets with detailed structural information, independent of molecular size, and accelerate development of stable, peptide-based therapeutics.

Keywords: D-peptide; X-ray crystallography; computational design; hemagglutinin; influenza.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:A patent application related to this work has been filed by some of the authors (J.J., D.B., R.V., and R.H.E.F) (application number PCT/EP2016/075916; publication number WO 2017/072222 Al). NIH grants R56 AI117675 and R56 AI127371.

References

    1. Lau J. L., Dunn M. K., Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg. Med. Chem. 26, 2700–2707 (2018). - PubMed
    1. Fosgerau K., Hoffmann T., Peptide therapeutics: Current status and future directions. Drug Discov. Today 20, 122–128 (2015). - PubMed
    1. Vlieghe P., Lisowski V., Martinez J., Khrestchatisky M., Synthetic therapeutic peptides: Science and market. Drug Discov. Today 15, 40–56 (2010). - PubMed
    1. Furman J. L., Chiu M., Hunter M. J., Early engineering approaches to improve peptide developability and manufacturability. AAPS J. 17, 111–120 (2015). - PMC - PubMed
    1. Hamamoto K., Kida Y., Zhang Y., Shimizu T., Kuwano K., Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol. Immunol. 46, 741–749 (2002). - PubMed

LinkOut - more resources